Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen

Shilpa Vishwanath, Fuad M. Baroody, Mohamad R. Chaaban, Marcella Detineo, Kenneth H. Lasser, Elliot C. Lasser, Robert M. Naclerio

Research output: Contribution to journalArticle

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)219-221
Number of pages3
JournalJournal of Allergy and Clinical Immunology
Volume128
Issue number1
DOIs
StatePublished - Jul 2011

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this